-
EP3362082
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3362082
| EP3362082 - METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 28.05.2021 Database last updated on 08.06.2024 | |
| Former | Examination is in progress Status updated on 07.02.2019 | ||
| Former | Request for examination was made Status updated on 20.07.2018 | ||
| Former | The international publication has been made Status updated on 21.04.2017 | ||
| Former | unknown Status updated on 31.10.2016 | Most recent event Tooltip | 28.05.2021 | Application deemed to be withdrawn | published on 30.06.2021 [2021/26] | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris / FR | For all designated states Université de Rouen Normandie 1 rue Thomas Becket 76130 Mont-Saint-Aignan / FR | For all designated states Université Paris Diderot - Paris 7 5, rue Thomas Mann 75013 Paris / FR | [2018/34] | Inventor(s) | 01 /
TAN, Yossan-Var UMR U905 - Université de Rouen Faculté de Médecine et Pharmacie Bâtiment Recherche 22 Boulevard Gambetta 76183 Rouen cedex / FR | 02 /
ABAD-RABAT, Catalina UMR U905 - Université de Rouen Faculté de Médecine et Pharmacie Bâtiment Recherche 22 Boulevard Gambetta 76183 Rouen cedex / FR | 03 /
COUVINEAU, Alain Inserm U1149/CRI/Univ P7 Faculté de Médecine Site Xavier Bichat 16 Rue Henri Huchard 75870 Paris Paris Cedex 18 / FR | 04 /
VOISIN, Thierry Inserm U1149/CRI/Univ P7 Faculté de Médecine Site Xavier Bichat 16 Rue Henri Huchard 75870 Paris Cedex 18 / FR | [2018/34] | Representative(s) | Inserm Transfert PariSanté Campus 10 rue d'Oradour-sur-Glane 75015 Paris / FR | [N/P] |
| Former [2018/34] | Collin, Matthieu Inserm-Transfert Paris Biopark 7, rue Watt 75013 Paris / FR | Application number, filing date | 16784461.2 | 14.10.2016 | [2018/34] | WO2016EP74806 | Priority number, date | EP20150306657 | 16.10.2015 Original published format: EP 15306657 | EP20160305146 | 08.02.2016 Original published format: EP 16305146 | [2018/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017064302 | Date: | 20.04.2017 | Language: | EN | [2017/16] | Type: | A1 Application with search report | No.: | EP3362082 | Date: | 22.08.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.04.2017 takes the place of the publication of the European patent application. | [2018/34] | Search report(s) | International search report - published on: | EP | 20.04.2017 | Classification | IPC: | A61K38/17, A61K38/22 | [2018/34] | CPC: |
A61K38/22 (EP,US);
C07K16/2869 (US);
A61P37/06 (EP,US);
A61P43/00 (EP,US);
C07K16/283 (US);
Y02A50/30 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/34] | Title | German: | VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG ENTZÜNDLICHER AUGENKRANKHEITEN | [2018/34] | English: | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES | [2018/34] | French: | MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES AUTO-IMMUNES | [2018/34] | Entry into regional phase | 16.04.2018 | National basic fee paid | 16.04.2018 | Designation fee(s) paid | 16.04.2018 | Examination fee paid | Examination procedure | 16.04.2018 | Amendment by applicant (claims and/or description) | 16.04.2018 | Examination requested [2018/34] | 16.04.2018 | Date on which the examining division has become responsible | 11.02.2019 | Despatch of a communication from the examining division (Time limit: M04) | 06.06.2019 | Reply to a communication from the examining division | 27.08.2019 | Despatch of a communication from the examining division (Time limit: M04) | 18.12.2019 | Reply to a communication from the examining division | 23.09.2020 | Despatch of a communication from the examining division (Time limit: M04) | 04.02.2021 | Application deemed to be withdrawn, date of legal effect [2021/26] | 24.02.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/26] | Fees paid | Renewal fee | 26.10.2018 | Renewal fee patent year 03 | 21.10.2019 | Renewal fee patent year 04 | 20.10.2020 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2008128981 (PROBIODRUG AG [DE], et al) [Y] 6-9 * page 30 *; | [XP]WO2015197572 (INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE [FR], et al) [XP] 6-9 * the whole document *; | [A] - LIH-CHU CHIOU ET AL, "Orexins/Hypocretins: Pain Regulation and Cellular Actions", CURRENT PHARMACEUTICAL DESIGN, NL, (20100901), vol. 16, no. 28, doi:10.2174/138161210793292483, ISSN 1381-6128, pages 3089 - 3100, XP055150506 [A] 6-9 * the whole document * DOI: http://dx.doi.org/10.2174/138161210793292483 | [Y] - DAVID ALEXANDRE ET AL, "The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis", EUROPEAN JOURNAL OF CANCER, (20140801), vol. 50, no. 12, doi:10.1016/j.ejca.2014.05.008, ISSN 0959-8049, pages 2126 - 2133, XP055196667 [Y] 6-9 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejca.2014.05.008 | by applicant | US4816567 | WO9007861 | US5225539 | US5229275 | US5545806 | US5545807 | US5565332 | US5567610 | US5573905 | US5585089 | US5591669 | US5598369 | US5693761 | US5693762 | US5859205 | US6150584 | - "A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage", NAT. MED., (2007), vol. 13, no. 2, pages 139 - 145 | - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495 | - WU ET AL., MOL. BIOL., (1999), vol. 294, page 151 | - PROC NATL ACAD SCI USA., (201207), vol. 106, no. 6, page 2009 |